AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
AbCellera Biologics Inc. (NASDAQ: ABCL ) is one of the most promising penny stocks under $5 to buy . On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a major transition into a clinical-stage biotechnology company. The firm ended the year with $75 million in total revenue, which was composed of $27 million from partnered programs and $48 million from licensing and royalties, while reporting a net loss of $146 million. This loss reflects a significant pivot toward internal pipeline development, as evidenced by a $187 million investment in R&D. The company's clinical pipeline saw substantial progress in 2025, highlighted by the advancement of its lead program, ABCL635, into Phase 2 studies for vasomotor symptoms/VMS. Encouraging target engagement data has notably increased the estimated probability of success for this program, with a major readout expected in the third quarter of 2026. AbCellera Biologics (ABCL) Pivots to Clinical St
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- AbCellera Reports Full Year 2025 Business ResultsBusiness Wire
- AbCellera Biologics (NASDAQ:ABCL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ABCL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- AbCellera to Present at Upcoming Investor Conferences in March and April 2026Business Wire
ABCL
Earnings
- 2/24/26 - Beat
ABCL
Sec Filings
- 3/2/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ABCL's page on the SEC website